Terns Pharmaceuticals, Inc.

TERNDelisted May 5, 2026

Industry: Pharmaceutical Preparations
SEC CIK: 0001831363

SEC filings (opens in a new tab)

Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 319 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 319; Q1 2026, +78 vs. previous quarter
13F value: $6.56B; Reported value at the end of Q1 2026
Superinvestors holding: 1; At the end of Q1 2026

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: –; No comparable prior period
Net income, FY2025: -$96.2M; No comparable prior period
Free cash flow, FY2025: -$82.2M; No comparable prior period
Revenue, Q4 FY2025: –; No comparable prior period

Short interest

See short data

From FINRA, settlement date Apr 30, 2026.

Short interest: 5.54M; Shares sold short
Change: −2.53M; −31.3% vs. previous
Days to cover: 1.46; At average daily volume

Superinvestors holding TERN, Q1 2026

Go to the superinvestors tab

1 superinvestor reports holding Terns Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

0.2%

Terns Pharmaceuticals, Inc.'s share of the portfolio

Shares: 321,905
Value: $17.0M

Latest insider trades

See all insider trades

Open-market purchases and sales by Terns Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Apr 2, 2026 (view filing)	Apr 1	1 day	Kuriakose EmilChief Medical Officer	SSale	−942	$52.75	−$49.7K	−0.9%105.7K after
Mar 17, 2026 (view filing)	Mar 16	1 day	Burroughs Amy L.Chief Executive Officer	SSale	−14.6K	$46.71	−$681.2K	−4.8%289.0K after	2 lots10b5-1
Feb 18, 2026 (view filing)	Feb 17	1 day	Burroughs Amy L.Chief Executive Officer	SSale	−14.6K	$39.20	−$571.6K	−4.8%289.0K after	3 lots10b5-1
Jan 16, 2026 (view filing)	Jan 15	1 day	Burroughs Amy L.Chief Executive Officer	SSale	−68.7K	$37.08	−$2.55M	−19.2%289.0K after	2 lots10b5-1
Jan 6, 2026 (view filing)	Jan 2	4 days	Kuriakose EmilChief Medical Officer	SSale	−1.16K	$38.57	−$44.6K	−2.2%50.4K after	2 lots
Jan 6, 2026 (view filing)	Jan 5	1 day	Burroughs Amy L.Chief Executive Officer	SSale	−71.3K	$38.10	−$2.72M	−33.9%139.0K after
Nov 5, 2025 (view filing)	Nov 4	1 day	Quigley Jill M.Director	SSale	−24.5K	$18.00	−$441.4K	−100.0%0 after	10b5-1
Oct 2, 2025 (view filing)	Oct 1	1 day	Kuriakose EmilChief Medical Officer	SSale	−944	$7.85	−$7.41K	−1.8%51.5K after
Jul 3, 2025 (view filing)	Jul 1	2 days	Kuriakose EmilChief Medical Officer	SSale	−853	$4.27	−$3.64K	−1.6%52.5K after
Jun 30, 2025 (view filing)	Jun 27	3 days	Gengos AndrewChief Financial Officer	PPurchase	+10.0K	$3.93	+$39.3K	+66.7%25.0K after	2 lots

Top 10 13F holders, Q1 2026

See all 319 holders

The largest institutional positions in Terns Pharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.

Institutions holding TERN in Q1 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	9,569,585	$504.5M	0.01%	+1,375,367+16.8%	Added
Morgan Stanley	6,449,140	$340.0M	0.02%	−1,496,468−18.8%	Reduced
Avoro Capital Advisors LLC	5,695,000	$300.2M	2.96%	+1,345,000+30.9%	Added
Vanguard Capital Management LLC	4,355,482	$229.6M	0.01%	+4,355,482	New
Holocene Advisors, LP	4,115,828	$217.0M	0.53%	+1,340,335+48.3%	Added
Citadel Advisors LLC	3,218,810	$169.7M	0.12%	+52,168+1.6%	Added
Millennium Management LLC	3,011,558	$158.8M	0.12%	+2,024,252+205.0%	Added
HBK Investments L P	2,950,000	$155.5M	1.96%	+2,950,000	New
JPMorgan Chase & Co	2,869,728	$151.8M	0.01%	+1,096,702+61.9%	Added
Lord, Abbett & Co. LLC	2,812,938	$148.3M	0.48%	+100,539+3.7%	Added

Holders of 5% or more of TERN

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Terns Pharmaceuticals, Inc..

Largest holders of TERN from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
BlackRock, Inc.	13G/A	6.80%5.74M shares	–	Oct 24, 20243 filings	Feb 5, 2025	SEC